Vgenfli

<p>Vgenfli is a medicine used to treat adults with:</p><ul><li>the ‘wet’ form of age-related macular degeneration (AMD), a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by choroidal neovascularisation (the abnormal growth of blood vessels under the macula), which may leak fluid and blood and cause swelling;</li><li>impaired vision due to macular oedema (swelling) that follows blockage of either the main vein carrying blood from the retina (known as central retinal vein occlusion, CRVO) or of smaller branch veins (known as branch retinal vein occlusion, BRVO);</li><li>impaired vision due to macular oedema caused by diabetes;</li><li>impaired vision due to choroidal neovascularisation in people with myopia (short-sightedness).</li></ul><p>Vgenfli contains the active substance aflibercept and is a biological medicine. It is a ‘biosimilar medicine’; this means that Vgenfli is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Vgenfli is Eylea. For more information on biosimilar medicines, see <a href="https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines">here</a>.</p>